Tarik Asselah
Overview
Explore the profile of Tarik Asselah including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
233
Citations
6090
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
de Ledinghen V, Fougerou-Leurent C, Le Pabic E, Pol S, Alfaiate D, Lacombe K, et al.
JHEP Rep
. 2024 Jul;
6(8):101057.
PMID: 39045338
Background & Aims: In France, bulevirtide (BLV) became available in September 2019 through an early access program to treat patients with HDV. The aim of this analysis was to evaluate...
12.
Asselah T, Chulanov V, Lampertico P, Wedemeyer H, Streinu-Cercel A, Pantea V, et al.
N Engl J Med
. 2024 Jun;
391(2):133-143.
PMID: 38842520
Background: In a phase 3 trial, bulevirtide monotherapy led to a virologic response in patients with chronic hepatitis D. Pegylated interferon (peginterferon) alfa-2a is recommended by guidelines as an off-label...
13.
De Broucker C, Asselah T
Saudi J Gastroenterol
. 2024 May;
30(3):123-125.
PMID: 38738542
No abstract available.
14.
Mateo R, Xu S, Shornikov A, Yazdi T, Liu Y, May L, et al.
JHEP Rep
. 2023 Nov;
5(11):100893.
PMID: 37929228
Background & Aims: Bulevirtide (BLV) is a small lipopeptide agent that specifically binds to the sodium taurocholate cotransporting polypeptide (NTCP) bile salt transporter and HBV/HDV receptor on the surface of...
15.
Asselah T
Clin Liver Dis
. 2023 Oct;
27(4):985-995.
PMID: 37778781
HDV use the cell enzymes for its own replication, and the HBsAg as an envelope. There is an urgent need to develop new drugs for chronic hepatitis D (CHD). Pegylated...
16.
Nasser N, Tonnerre P, Mansouri A, Asselah T
Curr Opin Virol
. 2023 Sep;
63:101360.
PMID: 37696687
An estimated 257 million people are chronic carriers of hepatitis-B virus (HBV) infection, which resulted in around 1 million deaths, mainly due to hepatocellular carcinoma (HCC). Long-term nucleotide analog treatment...
17.
Yuen M, Asselah T, Jacobson I, Brunetto M, Janssen H, Takehara T, et al.
Lancet Gastroenterol Hepatol
. 2023 Jul;
8(9):790-802.
PMID: 37442152
Background: JNJ-73763989 (JNJ-3989), a small interfering RNA, targets all hepatitis B virus (HBV) RNAs, reducing all HBV proteins. JNJ-56136379 (JNJ-6379; also known as bersacapavir), a capsid assembly modulator, inhibits HBV...
18.
19.
Costante F, Stella L, Santopaolo F, Gasbarrini A, Pompili M, Asselah T, et al.
J Hepatocell Carcinoma
. 2023 May;
10:713-724.
PMID: 37128594
Hepatitis D virus (HDV) infection affects more than 10 million people worldwide, with an estimated prevalence of nearly 4.5% among HBsAg-positive individuals. Epidemiological studies have shown a significant increase in...
20.
Hollnberger J, Liu Y, Xu S, Chang S, Martin R, Manhas S, et al.
J Hepatol
. 2023 Apr;
79(3):657-665.
PMID: 37120031
Background & Aims: Bulevirtide (BLV) is a HDV/HBV entry inhibitor that is associated with virologic response (responders, HDV-RNA undetectable or ≥2 log IU/ml decrease from baseline) in >50% of patients...